This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Dose Limiting Toxicities (DLT) of Experimental Regimens
Timeframe: Up to 28 days
Progression Free Survival (PFS) (Phase II)
Timeframe: From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years
PFS (Phase III)
Timeframe: From study enrollment to the investigator determined date of progression or death due to any cause, whichever occurs first, assessed up to 5 years.
Overall Survival (OS) (Phase III)
Timeframe: From study enrollment to the date of death regardless of the cause, assessed up to 5 years